{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:49:10Z","timestamp":1790981350592,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ejps.2017.10.012","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T02:17:16Z","timestamp":1507861036000},"page":"409-417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Eprosartan mesylate loaded bilosomes as potential nano-carriers against diabetic nephropathy in streptozotocin-induced diabetic rats"],"prefix":"10.1016","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8769-4564","authenticated-orcid":false,"given":"Abdul","family":"Ahad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Raish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajaz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad I.","family":"Al-Jenoobi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah M.","family":"Al-Mohizea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.10.012_bb0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpharm.2015.03.020","article-title":"Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study","volume":"485","author":"Abdelbary","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.10.012_bb0010","first-page":"1847","article-title":"Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide\/protein-based therapeutics or vaccines","volume":"23","author":"Aburahma","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2017.10.012_bb0015","first-page":"1","article-title":"Validation of a rapid and sensitive HPLC-UV method for the quantification of eprosartan mesylate in bulk drug, teventenTM and ultradeformable lipid based vesicular system","volume":"11","author":"Ahad","year":"2015","journal-title":"Curr. Pharm. Anal."},{"key":"10.1016\/j.ejps.2017.10.012_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10837450.2017.1330345","article-title":"Formulation and characterization of Phospholipon 90 G and tween 80 based transfersomes for transdermal delivery of eprosartan mesylate","author":"Ahad","year":"2017","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2017.10.012_bb0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biopha.2017.01.164","article-title":"Pharmacodynamic study of eprosartan mesylate-loaded transfersomes Carbopol(R) gel under Dermaroller(R) on rats with methyl prednisolone acetate-induced hypertension","volume":"89","author":"Ahad","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejps.2017.10.012_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2017.01.006","article-title":"Formulation and characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate","author":"Ahad","year":"2017","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.ejps.2017.10.012_bb0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijpharm.2015.03.033","article-title":"Investigating the potential of employing bilosomes as a novel vesicular carrier for transdermal delivery of tenoxicam","volume":"485","author":"Al-Mahallawi","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.10.012_bb0040","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jps.2600791202","article-title":"Optimization and upscaling of doxorubicin-containing liposomes for clinical use","volume":"79","author":"Amselem","year":"1990","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.10.012_bb0045","first-page":"4797","article-title":"Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge","volume":"10","author":"Arzani","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2017.10.012_bb0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijpharm.2009.04.022","article-title":"Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt","volume":"376","author":"Chen","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.10.012_bb0055","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1016\/S0264-410X(00)00537-5","article-title":"Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes)","volume":"19","author":"Conacher","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.ejps.2017.10.012_bb0060","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s13346-016-0318-7","article-title":"Formulation and statistical optimization of self-microemulsifying drug delivery system of eprosartan mesylate for improvement of oral bioavailability","volume":"6","author":"Dangre","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejps.2017.10.012_bb0065","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1440-1746.2007.05153.x","article-title":"Role of phosphatidylcholine saturation in preventing bile salt toxicity to gastrointestinal epithelia and membranes","volume":"23","author":"Dial","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejps.2017.10.012_bb0070","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.colsurfb.2008.12.030","article-title":"Development of different temoporfin-loaded invasomes-novel nanocarriers of temoporfin: characterization, stability and in vitro skin penetration studies","volume":"70","author":"Dragicevic-Curic","year":"2009","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejps.2017.10.012_bb0075","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.biopha.2016.04.001","article-title":"Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model","volume":"81","author":"El-Mahdy","year":"2016","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ejps.2017.10.012_bb0080","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fimmu.2015.00340","article-title":"Cellular and molecular mechanisms of chronic kidney disease with diabetes mellitus and cardiovascular diseases as its comorbidities","volume":"6","author":"Gajjala","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejps.2017.10.012_bb0085","first-page":"965","article-title":"Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt","volume":"6","author":"Guan","year":"2011","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2017.10.012_bb0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.colsurfb.2016.04.006","article-title":"Readily restoring freeze-dried probilosomes as potential nanocarriers for enhancing oral delivery of cyclosporine a","volume":"144","author":"Guan","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejps.2017.10.012_bb0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1517\/13543784.2014.892580","article-title":"Have we reached the limits for the treatment of diabetic nephropathy?","volume":"23","author":"Hajhosseiny","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejps.2017.10.012_bb0100","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.nano.2013.08.012","article-title":"Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration","volume":"10","author":"Jain","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejps.2017.10.012_bb0105","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.hjh.0000357904.71080.7d","article-title":"Effects of angiotensin II receptor blockers on diabetic nephropathy","volume":"27","author":"Kalaitzidis","year":"2009","journal-title":"J. Hypertens. Suppl."},{"key":"10.1016\/j.ejps.2017.10.012_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.08.032","article-title":"Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications","volume":"420","author":"Kawabata","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.10.012_bb0115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00004872-199501000-00015","article-title":"Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats","volume":"13","author":"Kohzuki","year":"1995","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejps.2017.10.012_bb0120","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/jhh.2008.19","article-title":"Effects of eprosartan on mitochondrial membrane potential and H2O2 levels in leucocytes in hypertension","volume":"22","author":"Labios","year":"2008","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.ejps.2017.10.012_bb0125","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3349\/ymj.2002.43.2.183","article-title":"Inducible nitric oxide synthase (iNOS) expression is increased in lipopolysaccharide (LPS)-stimulated diabetic rat glomeruli: effect of ACE inhibitor and angiotensin II receptor blocker","volume":"43","author":"Lee","year":"2002","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.ejps.2017.10.012_bb0130","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1046\/j.1523-1755.2000.07715.x","article-title":"Role of angiotensin II in diabetic nephropathy","volume":"77","author":"Leehey","year":"2000","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.ejps.2017.10.012_bb0135","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.trsl.2008.01.003","article-title":"Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats","volume":"151","author":"Leehey","year":"2008","journal-title":"Transl. Res."},{"key":"10.1016\/j.ejps.2017.10.012_bb0140","article-title":"Development of liposome containing sodium deoxycholate to enhance oral bioavailability of itraconazole","author":"Li","year":"2016","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.10.012_bb0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1208\/s12249-013-0034-2","article-title":"Enhanced topical delivery of finasteride using glyceryl monooleate-based liquid crystalline nanoparticles stabilized by cremophor surfactants","volume":"15","author":"Madheswaran","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejps.2017.10.012_bb0150","first-page":"1","article-title":"Improved hepatoprotective activity of silymarin via encapsulation in the novel vesicular nanosystem bilosomes","author":"Mohsen","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2017.10.012_bb0155","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejphar.2015.01.027","article-title":"Ameliorative effect of eprosartan on high-fat diet\/streptozotocin-induced early diabetic nephropathy in rats","volume":"750","author":"Morsy","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2017.10.012_bb0160","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1385\/CBB:43:2:289","article-title":"The role of oxidative stress in diabetic complications","volume":"43","author":"Niedowicz","year":"2005","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.ejps.2017.10.012_bb0165","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-409X(00)00121-6","article-title":"Lymphatic targeting with nanoparticulate system","volume":"47","author":"Nishioka","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2017.10.012_bb0170","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2012.02.009","article-title":"Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose","volume":"81","author":"Niu","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2017.10.012_bb0175","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2013.11.028","article-title":"Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study","volume":"460","author":"Niu","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.10.012_bb0180","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1046\/j.1523-1755.1999.00614.x","article-title":"Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure","volume":"56","author":"Noda","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejps.2017.10.012_bb0185","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2337\/diabetes.52.2.499","article-title":"Comparative trial of N-acetyl-cysteine, taurine, and oxerutin on skin and kidney damage in long-term experimental diabetes","volume":"52","author":"Odetti","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.ejps.2017.10.012_bb0190","article-title":"Angiotensin-(1-7): a novel peptide to treat hypertension and nephropathy in diabetes?","volume":"6","author":"Padda","year":"2015","journal-title":"J Diabetes Metab."},{"key":"10.1016\/j.ejps.2017.10.012_bb0195","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ijbiomac.2016.05.090","article-title":"Momordica charantia polysaccharides mitigate the progression of STZ induced diabetic nephropathy in rats","volume":"91","author":"Raish","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejps.2017.10.012_bb0200","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2217\/nnm.09.110","article-title":"Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery","volume":"5","author":"Roger","year":"2010","journal-title":"Nanomedicine (Lond.)"},{"key":"10.1016\/j.ejps.2017.10.012_bb0205","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1359-6446(01)02010-4","article-title":"Bilosomes: the answer to oral vaccine delivery?","volume":"6","author":"Senior","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2017.10.012_bb0210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.18433\/J3K01M","article-title":"Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes)","volume":"11","author":"Shukla","year":"2008","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.10.012_bb0215","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.drudis.2016.03.013","article-title":"Bilosomes in the context of oral immunization: development, challenges and opportunities","volume":"21","author":"Shukla","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2017.10.012_bb0220","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3892\/br.2013.183","article-title":"Renoprotective effects of olmesartan medoxomil on diabetic nephropathy in streptozotocin-induced diabetes in rats","volume":"2","author":"Si","year":"2014","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.ejps.2017.10.012_bb0225","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.phrs.2005.05.004","article-title":"Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening","volume":"52","author":"Srinivasan","year":"2005","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2017.10.012_bb0230","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/10611860801927598","article-title":"Pharmacokinetics and targeting property of TFu-loaded liposomes with different sizes after intravenous and oral administration","volume":"16","author":"Sun","year":"2008","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2017.10.012_bb0235","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/10717541003667764","article-title":"Liposomes incorporating sodium deoxycholate for hexamethylmelamine (HMM) oral delivery: development, characterization, and in vivo evaluation","volume":"17","author":"Sun","year":"2010","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejps.2017.10.012_bb0240","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1023\/A:1018945902276","article-title":"Uptake of phosphatidylserine liposomes by rat Peyer's patches following intraluminal administration","volume":"10","author":"Tomizawa","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.10.012_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-59745-542-8_1","article-title":"Origins of protein blotting","volume":"536","author":"Towbin","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejps.2017.10.012_bb0250","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.drudis.2007.09.005","article-title":"Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs","volume":"12","author":"Vasconcelos","year":"2007","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2017.10.012_bb0255","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.107.090472","article-title":"Angiotensin II-dependent superoxide: effects on hypertension and vascular dysfunction","volume":"52","author":"Welch","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.ejps.2017.10.012_bb0260","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/1061186X.2012.747528","article-title":"Characterization and optimization of bilosomes for oral vaccine delivery","volume":"21","author":"Wilkhu","year":"2013","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2017.10.012_bb0265","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejpb.2006.03.003","article-title":"A novel method to prepare highly encapsulated interferon-alpha-2b containing liposomes for intramuscular sustained release","volume":"64","author":"Yang","year":"2006","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2017.10.012_bb0270","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.2147\/IJN.S92665","article-title":"Enhanced oral bioavailability of silymarin using liposomes containing a bile salt: preparation by supercritical fluid technology and evaluation in vitro and in vivo","volume":"10","author":"Yang","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejps.2017.10.012_bb0275","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/1061186X.2013.789033","article-title":"Nanocarriers for oral drug delivery","volume":"21","author":"Zhang","year":"2013","journal-title":"J. Drug Target."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717305560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717305560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T20:48:03Z","timestamp":1536698883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717305560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":55,"alternative-id":["S0928098717305560"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.10.012","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eprosartan mesylate loaded bilosomes as potential nano-carriers against diabetic nephropathy in streptozotocin-induced diabetic rats","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}